scholarly journals Insulin Estimation and Prediction: A Review of the Estimation and Prediction of Subcutaneous Insulin Pharmacokinetics in Closed-Loop Glucose Control

2018 ◽  
Vol 38 (1) ◽  
pp. 47-66 ◽  
2017 ◽  
Vol 11 (4) ◽  
pp. 822-824 ◽  
Author(s):  
Eric Renard

While only used initially in cases with resistance to subcutaneous insulin therapy, intraperitoneal insulin therapy provides an overall more stable glucose control than subcutaneous insulin therapy thanks to its pharmacokinetics as pointed by Garcia-Verdugo et al from the experience of implantable insulin pumps. The expansion of these devices has been limited by underdelivery issues and high cost. The availability of a new percutaneous access to intraperitoneal route could allow a similar glucose control with less constraints of follow-up and expected lower cost. Currently reported clinical experience does not allow a reliable assessment of its main risk of infection which could impair its sustained usability. Because intraperitoneal insulin could allow a fully automated closed-loop insulin delivery, a specific interest for its means of performance is relevant.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 350-OR
Author(s):  
LIA BALLY ◽  
HOOD THABIT ◽  
SARA HARTNELL ◽  
EVELINE ANDEREGGEN ◽  
YUE RUAN ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Chun-xiu Gong ◽  
Li-ya Wei ◽  
Di Wu ◽  
Bing-yan Cao ◽  
Xi Meng ◽  
...  

Aims. To determine whether multiple daily injections (MDIs) or continuous subcutaneous insulin infusion (CSII) contributes to better glucose control in children with different type 1 diabetes duration.Methods. Subjects were grouped according to early (≤1 year after disease onset; 1A) or late (1–3 years after onset; 2A) MDIs/CSII treatment initiation. Corresponding control groups (1B, 2B) received insulin injections twice daily.Results. HbA1c levels were consistently lower in group 1A than in group 1B (6 months (T2): 7.37% versus 8.21%; 12 months (T3): 7.61% versus 8.41%; 24/36 months (T4/T5): 7.61% versus 8.72%; allP<0.05), but were lower in group 2A than in group 2B only at T2 (8.36% versus 9.19%;P=0.04). Levels were lower in group 1A than in group 2A when disease duration was matched (7.61% versus 8.49%;P<0.05). Logistic regression revealed no correlation between HbA1c level and MDIs/CSII therapy. HbA1c levels were only negatively related to insulin dosage.Conclusions. Blood glucose control was better in patients receiving MDIs/CSII than in those receiving conventional treatment. Early MDIs/CSII initiation resulted in prolonged maintenance of low HbA1c levels compared with late initiation. MDIs/CSII therapy should be combined with comprehensive management.


Diabetologia ◽  
2017 ◽  
Vol 60 (11) ◽  
pp. 2157-2167 ◽  
Author(s):  
Klemen Dovc ◽  
Maddalena Macedoni ◽  
Natasa Bratina ◽  
Dusanka Lepej ◽  
Revital Nimri ◽  
...  

2010 ◽  
Vol 27 (4) ◽  
pp. 480-484 ◽  
Author(s):  
D. Elleri ◽  
J. M. Allen ◽  
M. Nodale ◽  
M. E. Wilinska ◽  
C. L. Acerini ◽  
...  

2019 ◽  
Vol 80 (11) ◽  
pp. 665-669
Author(s):  
CK Boughton ◽  
R Hovorka

The prevalence of diabetes in the inpatient setting is increasing, and suboptimal glucose control in hospital is associated with increased morbidity and mortality. Attaining the recommended glucose levels is challenging with standard insulin therapy. Hypoglycaemia and hyperglycaemia are common and diabetes management in hospital can be a considerable workload burden for health-care professionals. Fully automated insulin delivery (closed-loop) has been shown to be safe, and achieves superior glucose control than standard insulin therapy in the hospital, including in those patients receiving haemodialysis and enteral or parenteral nutrition where glucose control can be particularly challenging. Evidence that the improved glucose control achieved using closed-loop systems can translate into improved clinical outcomes for patients is key to support widespread adoption of this technology. The closed-loop approach has the potential to provide a paradigm shift in the management of inpatient diabetes, particularly in the most challenging inpatient populations, and may reduce staff work burden and the health-care costs associated with inpatient diabetes.


Sign in / Sign up

Export Citation Format

Share Document